AI Summary & Key Takeaways
AI InsightFive-, 10-, and 15-yearoverall survival rates were 79%, 63%, and 63%, and 5-, 10- and 15-year progression-free survival rateswere 63%, 63%, and 63%, respectively.
📌 3 Key Takeaways
Abstract
OBJECTIVEThe aim of the present study was to evaluate treatment outcomes for adult patients with medulloblastomawho received craniospinal irradiation following surgery at Dokuz Eylül University Radiation OncologyDepartment.METHODSTwelve patients were evaluated retrospectively. Median age was 31 years (range: 18–55 years). Accordingto Chang staging system, 3 (25%) of the patients were T1, 2 (17%) were T2, 5 (42%) were T3, and 1 (8%)was T4; 1 patient could not be staged due to inadequate preoperative imaging. Tumor location, stage,presence of residual disease, duration between surgery and radiotherapy (RT), age, and sex were evaluatedas prognostic factors. Statistical analyses were conducted using Kaplan-Meier method and SPSS forWindows, Version 15.0 (SPSS Inc., Chicago, IL, USA).RESULTSMedian dose was 36 Gy (range: 32–44 Gy) to craniospinal field and 54 Gy (range: 50–56 Gy) to primarytumor location. Median follow-up time was 62 months (range: 4–212 months). Five-, 10-, and 15-yearoverall survival rates were 79%, 63%, and 63%, and 5-, 10- and 15-year progression-free survival rateswere 63%, 63%, and 63%, respectively. No statistically significant prognostic factor was found for survivalrate. Three (25%) patients developed serious hematological toxicity during RT course. No grade 3or 4 late side effect was observed.CONCLUSIONDespite the limited number of cases, results are consistent with the literature. Evaluation of features ofthis rare disease requires studies with larger number of.